Anaptys Announces Participation in September Investor Conferences
AnaptysBio (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, has announced its participation in three major investor conferences in September 2025.
The company's leadership, including CEO Daniel Faga, will participate in fireside chats and one-on-one investor meetings at the Cantor Global Healthcare Conference (Sept. 3), Wells Fargo Healthcare Conference (Sept. 4), and Stifel Virtual Immunology and Inflammation Forum (Sept. 16). All sessions will be available via webcast on the company's investor relations website.
AnaptysBio (Nasdaq: ANAB), azienda biotecnologica in fase clinica focalizzata su terapie di immunologia, ha comunicato la partecipazione a tre importanti conferenze per investitori a settembre 2025.
I vertici dell'azienda, compreso l'Amministratore Delegato Daniel Faga, prenderanno parte a colloqui informali e incontri one-to-one con investitori al Cantor Global Healthcare Conference (3 settembre), al Wells Fargo Healthcare Conference (4 settembre) e al Stifel Virtual Immunology and Inflammation Forum (16 settembre). Tutte le sessioni saranno trasmesse in webcast sul sito della investor relations della società.
AnaptysBio (Nasdaq: ANAB), una compañía biotecnológica en fase clínica especializada en terapias inmunológicas, ha anunciado su participación en tres importantes conferencias para inversores en septiembre de 2025.
La dirección de la empresa, incluido el CEO Daniel Faga, intervendrá en charlas informales y mantendrá reuniones individuales con inversores en el Cantor Global Healthcare Conference (3 de septiembre), el Wells Fargo Healthcare Conference (4 de septiembre) y el Stifel Virtual Immunology and Inflammation Forum (16 de septiembre). Todas las sesiones se emitirán por webcast en la web de relaciones con inversores de la compañía.
AnaptysBio (Nasdaq: ANAB), 면역학 치료제에 특화된 임상 단계의 바이오테크 기업이 2025년 9월 개최되는 주요 투자자 컨퍼런스 세 곳에 참가한다고 발표했습니다.
CEO 다니엘 파가(Daniel Faga)를 포함한 회사 경영진은 Cantor Global Healthcare Conference(9월 3일), Wells Fargo Healthcare Conference(9월 4일), Stifel Virtual Immunology and Inflammation Forum(9월 16일)에서 파이어사이드 토크와 1:1 투자자 미팅에 참여합니다. 모든 세션은 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
AnaptysBio (Nasdaq: ANAB), société biotechnologique en phase clinique spécialisée dans les thérapies en immunologie, a annoncé sa participation à trois grandes conférences investisseurs en septembre 2025.
La direction de l'entreprise, y compris le PDG Daniel Faga, interviendra lors de discussions informelles et de réunions individuelles avec des investisseurs au Cantor Global Healthcare Conference (3 septembre), au Wells Fargo Healthcare Conference (4 septembre) et au Stifel Virtual Immunology and Inflammation Forum (16 septembre). Toutes les sessions seront diffusées en webcast sur le site relations investisseurs de la société.
AnaptysBio (Nasdaq: ANAB), ein biotechnologisches Unternehmen in der klinischen Phase mit Schwerpunkt auf immunologischen Therapien, gab seine Teilnahme an drei wichtigen Investorenkonferenzen im September 2025 bekannt.
Die Unternehmensleitung, darunter CEO Daniel Faga, wird an Fireside-Chats und Einzelgesprächen mit Investoren beim Cantor Global Healthcare Conference (3. Sept.), dem Wells Fargo Healthcare Conference (4. Sept.) und dem Stifel Virtual Immunology and Inflammation Forum (16. Sept.) teilnehmen. Alle Sitzungen werden per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
Cantor Global Healthcare Conference 2025, New York, NY
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, Sept. 3, 2025 at 8:00am ET / 5:00am PT
2025 Wells Fargo Healthcare Conference, Boston, MA
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Thursday, Sept. 4, 2025 at 11:00am ET / 8:00am PT
Stifel 2025 Virtual Immunology and Inflammation Forum, Virtual
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Sept. 16, 2025 at 12:00pm ET / 9:00am PT
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, being studied in celiac disease and ANB101, a BDCA2 modulator, both in Phase 1 trials. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio (ANAB) presenting at the Cantor Global Healthcare Conference 2025?
How can investors access AnaptysBio's conference presentations in September 2025?
Which investor conferences will AnaptysBio (ANAB) attend in September 2025?
Who will represent AnaptysBio at the September 2025 investor conferences?
